Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$118.35 USD
-2.11 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $118.42 +0.07 (0.06%) 6:54 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 21 - 40 ( 316 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurocrine Shifts Focus Towards Neurology, Eyeing at Movement Disorder Diseases and Psychosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
If Cash Is King In Biotech, Pipelines Are The Queens
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for NBIX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Setting Expectations For the NBI-921352 FOS Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Crinecerfont Wins Over Androgens Across Patient Age Groups; Reiterate Buy and PT Up to $150
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Pediatric Phase 3 CAHtalyst Offers Another Pipeline Win
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
With Crinecerfont?s Success, Neurocrine Expands Footprint to Endocrinology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Adult Phase 3 CAHtalyst Hits; Pediatric Data Remains On Track For Early 4Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza?s New Approval, Has an Edge Over Competitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A